REG - Alliance Pharma PLC - Publication of Annual Report and Accounts

Alliance PharmaAnnouncement

09/04/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250409:nRSI3487Ea&default-theme=true

RNS Number : 3487E  Alliance Pharma PLC  09 April 2025

 

 For immediate release
                        9 April 2025

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Publication of Annual Report and Accounts

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that the Annual Report & Accounts for the year ended 31 December 2024 was
published and made available today, 9 April 2025, on the Group's website:
www.alliancepharmaceuticals.com (http://www.alliancepharmaceuticals.com) .

 

A printed copy of the annual report is available on request by contacting
Burson Buchanan by email at alliancepharma@buchanan.uk.com
(mailto:alliancepharma@buchanan.uk.com) or by telephoning 020 7466 5000.

 

 

For further information:

 

 Alliance Pharma plc                                         + 44 (0)1249 466966
 Head of Investor Relations & Corporate Communications:      + 44 (0)1249 705168

 Cora McCallum
 ir@allianceph.comk

 Burson Buchanan                                             + 44 (0)20 7466 5000
 Mark Court / Sophie Wills
 alliancepharma@buchanan.uk.com

 Deutsche Numis (Nominated Adviser and Joint Broker)         + 44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Sher Shah

 

 Investec Bank plc (Joint Broker)    + 44 (0) 20 7597 5970
 Patrick Robb / Maria Gomez de Olea

 

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 290 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands.

For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com (http://www.alliancepharmaceuticals.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSUKSARVNUSRAR